プラダーウィリー症候群の世界市場-2022-2029

市場力学

主な原動力は、規制当局による特効薬指定の増加、診断対象患者数の増加、ヒト成長ホルモン療法適用率の上昇、強力なパイプライン、戦略的提携の拡大、PWSの診断・治療における先端技術の活用、認知度の高まりです。

プラダーウィリー症候群の治療に関する継続的な研究が、市場の成長を後押ししています。

プラダーウィリー症候群を治療するための進行中の研究は、世界市場の成長を後押ししています。例えば、Clinical Trials.govによると、現在3つの研究が活発に行われています。govによると、現在、3つの研究が活発に行われています。すなわち、Harmony Biosciences, LLCがスポンサーとなり、プラダーウィリー症候群の患者におけるピトリスアントの安全性と有効性を評価するための無作為化二重盲検プラセボ対照第2相試験、それに続く非盲検延長試験、2022年10月に完了すると推定される第3相多施設非盲検試験。プラダーウィリー症候群の患者さんにおけるソマトロピンの有効性と安全性を評価するための多施設共同非盲検マルチコホート試験（Pfizer社主催、2024年5月25日終了予定）、およびプラダーウィリー症候群の患者さんにおけるジアゾキシド・コリン徐放錠の非盲検長期安全性評価（Soleno Therapeutics, Inc.社主催、2023年6月完了予定）。によるプラダーウィリー症候群患者を対象とした非盲検長期安全性評価試験（2023年6月終了予定）です。さらに、プラダーウィリー症候群に対するさまざまな介入に関するさらなる12の研究が現在募集中であり、世界市場の成長を促進しています。

認知度の低さと治療効率の低さがプラダーウィリー症候群（PWS）市場の成長を鈍化させています。

しかし、現在の治療法の限られた効果、プラダーウィリー症候群の認知度の低さ、疾患に伴う合併症の存在が、市場の成長を抑制すると予想されます。

プラダーウィリー症候群（PWS）市場-業界分析

プラダーウィリー症候群（PWS）市場レポートでは、Porter`s Five forces、研究開発、疫学、規制、価格、パイプライン分析など、様々な業界要因に基づく市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19は、世界のプラダーウィリー症候群（PWS）市場の成長に深い影響を与えた非定型の健康問題です。その発生過程で、人々の交際に関する感染拡大を抑制するために、さまざまな規制機関によって制限が課されました。そのため、プラダーウィリー症候群（PWS）の多くの症例が未検出のまま、時間通りに定期健診を受けることが難しくなっています。さらに、輸送上の制約が輸出入に影響し、多くの市場関係者のサプライチェーンに影響を与え、全体として市場におけるプラダーウィリー症候群（PWS）の入手性を低下させ、売上を減少させ、世界的に市場の成長にマイナスの影響を及ぼしました。

プラダーウィリー症候群（PWS）市場レポートでは、約40以上の市場データ表、45以上の図、200ページ（概算）の範囲でのアクセスを提供することになります。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 調査・研究開発
    • 市場戦略
  • 抑制要因
    • 認知度の低さ
    • 低い治療効果
    • 厳しい規制機関
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学分析
• 研究と開発
• パイプライン分析
• サプライチェーン分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 製品タイプ別

• リコンビナント成長ホルモン
• ベロラニブ
• ベタヒスチン塩酸塩
• ジアゾキシドコリンCR
• FE-992097
• その他

第8章 販売チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 投与経路別

• 経口
• 注射剤

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク

第12章 企業プロファイル

• Pfizer
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Novartis
• Soleno Therapeutics
• Saniona
• Millendo Therapeutics, Inc.
• Levo Therapeutics, Inc.
• Rhythm Pharmaceuticals
• Essentialis, Inc.
• LG Corp
• Novo Nordisk

第13章 DataM

Market Overview

Prader-Willi syndrome market is expected to grow at a CAGR of 4.5% in the forecast period (2022-2029).

Prader-Willi syndrome (PWS) is a genetic disorder due to the deletion of a part of the father's chromosome 15. Prader-Willi syndrome can also be due to the presence of two copies of chromosome 15 inherited by the mother only, leading to their suppression during gene formation. PWS therapeutics have a wide scope in the global market, as no known cure is available for such a complex genetic disorder.

Market Dynamics

The major driving forces are increasing the number of special drug designations from regulatory bodies, an increasing number of the diagnosed patient population, growing human growth hormone therapy coverage rate, a strong pipeline, growing strategic alliances, use of advanced technologies for the diagnosis and treatment of PWS, and surging awareness.

The ongoing research on treating Prader-Willi syndrome is pushing the market's growth.

The ongoing studies for treating Prader-Willi syndrome are fueling the global market growth. For instance, according to Clinical Trials.gov currently, 3 studies are active; namely, a study sponsored by Harmony Biosciences, LLC titled a randomized, double-blind, placebo-controlled phase 2 study to evaluate the safety and the efficacy of Pitolisant in patients with Prader-Willi syndrome, followed by an open-label extension, which is estimated to complete by October 2022, a phase 3 multicenter, open-label, multi-cohort study for evaluation of the efficacy and safety of somatropin in Japanese participants with Prader-Willi syndrome (PWS) study sponsored by Pfizer, with the estimated completion on May 25, 2024, and an open-label, long-term safety evaluation of diazoxide choline controlled-release tablet in patients with Prader-Willi syndrome sponsored by Soleno Therapeutics, Inc. with estimated completion on June 2023. Furthermore, 12 more studies on different interventions for Prader-Willi syndrome are currently recruiting, driving the global market growth.

The lack of awareness and limited treatment efficiency slows the Prader-Willi syndrome (PWS) market growth.

However, the limited efficacy of the current therapies, lack of awareness of the Prader-Willi syndrome, and the presence of complications associated with the diseases are expected to restrain the market growth.

Prader-Willi syndrome (PWS) Market-Industry analysis.

The Prader-Willi syndrome (PWS) market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, pipeline analysis, Etc.

COVID-19 Impact Analysis

COVID-19 is an atypical health concern that has profoundly impacted the global Prader-Willi syndrome (PWS) market growth. In the course of the outbreak, restrictions were imposed by different regulatory bodies for controlling the spread of the infection regarding the socializing of people, which made it difficult to get regular healthcare check-ups on time leaving many cases of Prader-Willi syndrome (PWS) undetected. Moreover, the restrictions on transportation affected the import and export, affecting the supply chain of many market players, overall reducing the availability of Prader-Willi syndrome (PWS) in the market, reducing sales, and negatively impacting the market growth globally.

Segment Analysis

The recombinant growth hormone treatment for Prader-Willi syndrome (PWS) is estimated to oppress the market during the forecast period (2022-2029).

The recombinant growth hormones segment is expected to grow rapidly over the forecast period (2022-2029). Currently, the pharmacological management of Prader-Willi syndrome (PWS) focuses mainly on using human growth hormone (HGH) supplementation, which is approved in the US. Growth hormone(GH) supplementation constitutes the primary component of the entire therapeutic market composition due to the nearly ubiquitous deficiency of growth hormone (GH) in PWS patients. Some majorly approved GH therapies include Pfizer's Genotropin (somatropin), other major brands such as Norditropin (Novo Nordisk), and others in the US. Another approved drug is Omnitrope (somatropin [rDNA origin] injection) from Sandoz. Also, ongoing clinical trials on growth hormones are expected to boost the market growth. For instance, a study sponsored by OPKO Health, Inc. on safety and dose-finding study of different MOD-4023 dose levels compared to daily R-human Growth Hormone (hGH) therapy in pre-pubertal growth hormone deficient children is estimated to complete on December 12, 2024, another phase 3, open-label, randomized, multicenter, 12 months, study on the efficacy and the safety of weekly MOD-4023 compared to daily Genotropin - therapy in pre-pubertal children with growth hormone deficiency sponsored by OPKO Health, Inc. and estimated completion is in December 2022.

Geographical Analysis

North America is predicted to hold most of the market share.

North America oppressed the global Prader-Willi syndrome market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the increasing prevalence of Prader-Willi syndrome in the region and a growing number of ongoing research and development activities on the Prader-Willi syndrome. For instance, according to the National Institute of Health, the number of individuals with Prader Willi Syndrome is approximately 400000, and 20000 of these cases are in the United States. The presence of organizations creating awareness about PWS in the region is also expected to drive market growth. For instance, the Prader-Willi Syndrome Association (USA) has provided life-saving research, crisis, family support, medical and new parent support since 1975 and The Foundation for Prader-Willi Research, a non-profit corporation established in 2003. Furthermore, the presence of highly advanced and robust healthcare infrastructures in North America contributes to its dominance over the global Prader-Willi syndrome market.

Competitive Landscape

The key players operating in the global Prader-Willi syndrome market are Novartis, Soleno Therapeutics, Saniona, Pfizer, Millendo Therapeutics, Inc., Levo Therapeutics, Inc., Rhythm Pharmaceuticals, Essentialis, Inc., LG Corp and Novo Nordisk. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Prader-Willi syndrome market globally. For instance, on Aug 25, 2022, Novartis announced to spin off the Sandoz business creating a standalone company. Also, on July 20, 2022, FDA acknowledged that data from a randomized withdrawal period of Study C602 by Soleno Therapeutics have the potential to support an NDA submission.

Pfizer Inc.

Overview

Pfizer is an American multinational pharmaceutical and biotechnology corporation founded in 1849 and headquartered in the United States. Pfizer is continuously researching and developing new drug products for various diseases.

Product Portfolio

Pfizer`s Prader-Willi syndrome (PWS) product portfolio has Genotropin and NGENLA.

The Prader-Willi syndrome (PWS) market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Research and Development
    • 4.1.1.2. Market Strategies
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Awareness
    • 4.1.2.2. Low Efficacy of Treatment
    • 4.1.2.3. Stringent Regulatory Bodies
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiological Analysis
• 5.3. Research and Developments
• 5.4. Pipeline Analysis
• 5.5. Supply Chain Analysis
• 5.6. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.1.2. Market Attractiveness Index, By Product Type Segment
• 7.2. Recombinant Growth Hormone
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Beloranib
• 7.4. Betahistine Hydrochloride
• 7.5. Diazoxide Choline CR
• 7.6. FE-992097
• 7.7. Others

8. By Distribution Channels

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment.
  • 8.1.2. Market Attractiveness Index, By Distribution Channels Segment
• 8.2. Hospital Pharmacy
  • 8.3.1. Introduction
  • 8.3.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.4. Retail Pharmacy
• 8.5. Online Pharmacy

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
• 9.2. Oral
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Injectable

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Company Profiles

• 12.1. Pfizer
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Novartis
• 12.3. Soleno Therapeutics
• 12.4. Saniona
• 12.5. Millendo Therapeutics, Inc.
• 12.6. Levo Therapeutics, Inc.
• 12.7. Rhythm Pharmaceuticals
• 12.8. Essentialis, Inc.
• 12.9. LG Corp
• 12.10. Novo Nordisk

LIST NOT EXHAUSTIVE

13. DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact